UBE2C and prostate carcinoma: For instance, a UBE2C transcription inhibitor, CCI-779 [37], and a UBE2C-proteasome inhibitor, Bortezomib [38], blocked cell cycle progression in prostate cancer cells and colorectal carcinoma, respectively.